Levosimendan News and Research

RSS

Which biomarkers can help predict severe COVID-19?

The ability to detect potentially fatal illness early on in the course of the disease would enable a swift prioritization of these high-risk individuals for treatment. A new preprint on the medRxiv* server presents an array of biomarkers that may help achieve this laudable goal.

15 Mar 2021

No significant research undertaken to prevent or treat PPCM in healthy pregnant women, study reveals

Peripartum cardiomyopathy (PPCM) is a rare disorder characterized by weakened pumping of the heart, or "left ventricular dysfunction," which results in otherwise healthy pregnant women experiencing heart failure shortly before or up to five months after they deliver healthy babies. Despite the seriousness of this condition, a new study published in the Canadian Journal of Cardiology revealed that no significant research has been undertaken to explore how to prevent or treat this disorder.

16 Jul 2015

Oxygen Biotherapeutics announces publication of Phase 3 trial protocol for levosimendan

Oxygen Biotherapeutics, Inc. ("OBI") a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced that the protocol of their phase 3 trial for levosimendan has been published on ClinicalTrials.gov, "Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass."

7 Jan 2014

Broken heart syndrome arms against epinephrine high

Takotsubo cardiomyopathy, or “broken heart syndrome,” may actually protect the heart from very high levels of epinephrine, suggest results from an animal study.

10 Jul 2012

Broken heart syndrome arms against epinephrine high

Takotsubo cardiomyopathy, or “broken heart syndrome,” may actually protect the heart from very high levels of epinephrine, suggest results from an animal study.

10 Jul 2012

Broken heart syndrome may protect the heart from adrenaline overload

A condition that temporarily causes heart failure in people who experience severe stress might actually protect the heart from very high levels of adrenaline, according to a new study published in the journal Circulation. The research provides the first physiological explanation for Takotsubo cardiomyopathy, also called "broken heart syndrome" because it affects people who suffer severe emotional stress after bereavement, and suggests guidance for treatment.

27 Jun 2012

Levosimendan may effectively improve muscle function in patients with respiratory failure

Treatment with the calcium-sensitizing drug levosimendan may be effective in improving muscle function in patients with respiratory muscle weakness, which often accompanies chronic diseases such as chronic obstructive pulmonary disease (COPD) and congestive heart failure, according to researchers in the Netherlands, who studied the effects of the drug on healthy volunteers.

23 Sep 2011

Better treatment selection and improved therapies hold the key to improving prognosis in acute heart failure

Today, acute heart failure represents the most common reason for hospitalisation in the over-65 population.

31 May 2009

Levosimendan compared to dobutamine for decompensated heart failure

The drug levosimendan did not improve survival for patients with decompensated heart failure when compared with a more widely-used treatment for this condition, dobutamine, according to a study in the May 2 issue of JAMA.

2 May 2007